Chicharros USA - bolsa internacional

DCTH

News, esta vez (al fin) positivas.

http://www.otcmarkets.com/stock/DCTH/news/Favorable-Results-from-a-Multi-Center-Analysis-of-Delcath-PHP-Therapy-to-be-Published-in-Journal-of-Surgical-Oncology?id=177202

http://delcath.com/reuters-news/?id=2321097

Favorable Results from a Multi-Center Analysis of Delcath PHP Therapy to be Published in Journal of Surgical Oncology

Delcath Systems announces that results of a multi-center retrospective analysis of Delcath’s PHP^®Therapy have been accepted for publication in the peer-reviewed Journal of Surgical Oncology. The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by researchers from Moffitt Cancer Center in Tampa, FL and the University Hospital Southampton in the United Kingdom. The publication of the data is expected in an upcoming edition of the Journal.  An  abstract of this study was presented at the 12^th Annual Regional Therapies International Symposium in Snowbird, Utah in February 2017.  

Commenting on the announcement, Jennifer K. Simpson, Ph.D., President and CEO of Delcath Systems, said, “this study represents the largest data set outside of a controlled clinical trial on the use of PHP Therapy in the treatment of uveal melanoma metastatic to the liver. Preliminary results of the study presented at the Regional Therapies conference earlier this year showed data indicating tumor response and overall survival benefit with PHP Therapy beyond the 6-8 months seen with other therapies in this patient population. The most common serious side effects following treatment were anemia, thrombocytopenia and neutropenia; these were expected and the majority managed with supportive care. The preliminary data provide confidence that our Phase 3 clinical trial in ocular melanoma liver metastases can provide the evidence necessary to support an application for a labeled indication in this tumor type, and we look forward to the publication of the full study results.”

GALT

Ese Mugui.

Veo que el mínimo ha sido 1.20, y si el fail es de una F-2, es posible que enn sesión los vuelva a tocar, creo que mejor las voy a observar.

Fíjate si serán trileros, que ayer tuvo un AH de +50%.

DCTH

Buf, new del montón total, suena a nada nuevo, y a un "vamos bien". Prácticamente anuncian que lo que dijeron en Alemania se lo van a publicar en una revista.

Voy a ver los bid/ask, me extrañaría mucho que los americanos fueran tan tontos de subirla con esta caca de new.

BT

llego tarde a ver que me siente....

CUR

hubo new ? las llevo a 1.50 ay señorrrrrrrrrrrrrr mucho fuego artificial pero na de na

Buenas tardes,

HMNY -15%

Valen 10.21$, veis rebote?

En la última corrección bajaron hasta los 9$

Buenas tardes,
TROV se estan portando un poco mal, pero bueno, tienen pipeline surtidito con varios catalysts posibles, y dinero para un tiempo, no voy a esperarme que descubran la cura panacea del cancer, pero si aprovechar posibles calentones, me siento comodo estando en estas aunque podría haber entrado a mejor precio si,

Ahí van las CUR....

CUR

Resultados positivos en una fase 2. No se más.